Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data In Patients With Schizophrenia
Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today positive results from the first phase 3 clinical trial for lurasidone, which is under clinical development globally, for the treatment of patients with schizophrenia. In this six-week, double-blind, placebo-controlled trial, lurasidone 80 mg/day was significantly more effective than placebo for the treatment of acute schizophrenia. In addition, lurasidone was well-tolerated and had a relatively low discontinuation rate. The findings were presented at the 162nd Annual Meeting of the American Psychiatric Association in San Francisco, held on May 16-21.
generic viagra online
Patient-Centered Research Report Sent To Congress Outlining Research Priorities
Recommendations for how the HHS Office of the Secretary will spend $400 million in funds for patient-centered research, also known as comparative effectiveness research, were released by Federal Coordinating Council for Comparative Effectiveness Research (CER). The report, mandated by the American Recovery and Reinvestment Act, is designed to help the HHS Secretary and lawmakers improve the quality of care for patients, and provide patients and doctors the best information possible to make decisions about health care.
News of the day
H1N1 Spread Continues Worldwide; First Death In Asia Confirmed
The H1N1 (swine flu) virus has now infected more than 52,000 people, leaving 231 dead, the WHO said Monday, AFP/Washington Post reports. "Swine flu has now been reported in 100 countries and territories, and figures yet to be incorporated into the U.N. health agency"s official figures indicate an even higher toll," AFP/Washington Post writes, adding, "The WHO said, however, that its figures could not be considered reliable because some countries were no longer keeping total figures while other poor countries did not have the means to reliably detect cases." Since Friday, the number of cases has grown by more than 7,873 cases and 51 deaths, "highlighting the steady spread of the virus," the newspaper writes (AFP/Washington Post, 6/23).
Public Health

Poxel SAS Set Up To Find Innovative Solutions For Metabolic Diseases Management

Poxel is a research integrated pharmaceutical Company (RIPCO), spun out from Merck Serono a division of Merck KGaA, Germany, following the decision of Merck Serono to no longer invest in diabetes research and development. It aims to advance promising assets for cardio-metabolic diseases (with a primary focus on Type 2 diabetes) from Research to Phase 2 Clinical Proof-of-Concept, before out-licensing these projects to major pharmaceutical companies. Its pipeline consists only of innovative projects with new mechanisms of action, with a combined activity on glucose metabolism and other cardiovascular risk factors (lipid disorders and obesity) and with an improved safety profile compared to currently available therapies. Poxel has secured several programs from the Merck Serono pipeline. These include a first-in-class project, Imeglimin -which has already achieved its clinical proof-of-concept for the Type 2 diabetes monotherapy indication- and other projects from the Research until close to clinical development stages. Poxel"s management is composed of a tight and seasoned team of professionals who previously led the Merck Serono diabetes franchise from Research to Clinical & Commercialization. They have a proven track record in the pharmaceutical industry and extensive skills both in project management and technical expertise. The whole management team has an integrated strategic and operational view of the product value chain, from Research to Marketing, covering the complete product life cycle. Poxel"s team will perform and coordinate all work required in the following areas: research, preclinical, clinical and business development, with a strong focus on cardio-metabolic diseases. A focused and streamlined development of the company assets will ensure a successful out-licensing of those assets. All this provides Poxel with a significant competitive advantage. Poxel"s team will be advised by a highly regarded scientific Advisory Board in Endocrinology and Nutrition from the US and Europe. Poxel will start the development of its core assets, while seeking funding in order to create additional value from its unique pipeline. Neither Merck KGaA nor Merck Serono is shareholders of Poxel. About Type 2 Diabetes Type 2 Diabetes is defined by a failure of sensitive tissues to respond to insulin, a hormone involved in glucose and fatty acid metabolism, Type 2 diabetes hence being known as non-insulin-dependent diabetes. 90% of diabetic patients in the world suffer from type 2 diabetes. In 2007, more than 220 million people suffered from Type 2 diabetes worldwide, including over 65 million patients in the US and Europe. It is predicted that more than 300 million patients will have this disease by 2025 (IDF). The market is about EUR bn9.6 turnover in 2007, expected to reach EUR bn15 by 2016. Existing therapies on the market are dominated by few dominant product classes, but significant unmet needs remain. Poxel SAS


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009